720 related articles for article (PubMed ID: 16414267)
21. [Intranasal priming with HIV DNA vaccine and systemic boosting with recombinant vaccinia induce vigorous immune responses: experiment with mice].
Huang XG; Xu JQ; Ren L; Qiu C; Zhang N; Liu LX; Wan YM; Peng H; Shao YM
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(44):3109-13. PubMed ID: 17313761
[TBL] [Abstract][Full Text] [Related]
22. [Intranasal immunization with mucosal complex vaccine protects mice against Toxoplasma gondii].
Yin GR; Meng XL; Ma GY; Ma XM
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Aug; 25(4):290-4. PubMed ID: 18038798
[TBL] [Abstract][Full Text] [Related]
23. Mucosal vaccination strategies for women.
Kozlowski PA; Cu-Uvin S; Neutra MR; Flanigan TP
J Infect Dis; 1999 May; 179 Suppl 3():S493-8. PubMed ID: 10099127
[TBL] [Abstract][Full Text] [Related]
24. [Detection of LOS-specific antibody-secreting cells by ELISPOT assay].
Jiao XA; Hirano T; Gu XX
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 May; 20(3):366-9. PubMed ID: 15193241
[TBL] [Abstract][Full Text] [Related]
25. Mucosal memory B cells retain the ability to produce IgM antibodies 2 years after oral immunization.
Vajdy M; Lycke N
Immunology; 1995 Nov; 86(3):336-42. PubMed ID: 8550068
[TBL] [Abstract][Full Text] [Related]
26. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.
Patel GB; Zhou H; Ponce A; Chen W
Vaccine; 2007 Dec; 25(51):8622-36. PubMed ID: 17959279
[TBL] [Abstract][Full Text] [Related]
27. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation.
Buonaguro L; Visciano ML; Tornesello ML; Tagliamonte M; Biryahwaho B; Buonaguro FM
J Virol; 2005 Jun; 79(11):7059-67. PubMed ID: 15890945
[TBL] [Abstract][Full Text] [Related]
28. Reduction of nasal colonization of nontypeable Haemophilus influenzae following intranasal immunization with rLP4/rLP6/UspA2 proteins combined with aqueous formulation of RC529.
Mason KW; Zhu D; Scheuer CA; McMichael JC; Zlotnick GW; Green BA
Vaccine; 2004 Sep; 22(25-26):3449-56. PubMed ID: 15308371
[TBL] [Abstract][Full Text] [Related]
29. Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice.
Akagi T; Kawamura M; Ueno M; Hiraishi K; Adachi M; Serizawa T; Akashi M; Baba M
J Med Virol; 2003 Feb; 69(2):163-72. PubMed ID: 12683403
[TBL] [Abstract][Full Text] [Related]
30. [C3d molecular adjuvant increases the immunity of human chorionic gonadotropin beta DNA contraceptive vaccination and changes its immune response from Th1 to Th2].
Zhao XR; Li DJ; Yuan MM; Cai LR; Sun XX
Zhonghua Yi Xue Za Zhi; 2003 Nov; 83(21):1906-9. PubMed ID: 14642077
[TBL] [Abstract][Full Text] [Related]
31. Mucosal application of plasmid-encoded IL-15 sustains a highly protective anti-Herpes simplex virus immunity.
Toka FN; Rouse BT
J Leukoc Biol; 2005 Jul; 78(1):178-86. PubMed ID: 15817700
[TBL] [Abstract][Full Text] [Related]
32. Oral administration of type-II collagen peptide 250-270 suppresses specific cellular and humoral immune response in collagen-induced arthritis.
Zhu P; Li XY; Wang HK; Jia JF; Zheng ZH; Ding J; Fan CM
Clin Immunol; 2007 Jan; 122(1):75-84. PubMed ID: 17045846
[TBL] [Abstract][Full Text] [Related]
33. Induction of systemic and mucosal immune responses following immunization with somatostatin-avidin complexes incorporated into ISCOMS.
Estrada A; Laarveld B; Li B; Redmond MJ
Immunol Invest; 1995 Aug; 24(5):819-28. PubMed ID: 8543345
[TBL] [Abstract][Full Text] [Related]
34. Induction of antigen-specific immune responses by oral vaccination with Saccharomyces cerevisiae expressing Actinobacillus pleuropneumoniae ApxIIA.
Shin SJ; Bae JL; Cho YW; Lee DY; Kim DH; Yang MS; Jang YS; Yoo HS
FEMS Immunol Med Microbiol; 2005 Feb; 43(2):155-64. PubMed ID: 15681145
[TBL] [Abstract][Full Text] [Related]
35. Genetic immunization with the free human chorionic gonadotropin beta subunit elicits cytotoxic T lymphocyte responses and protects against tumor formation in mice.
Geissler M; Wands G; Gesien A; de la Monte S; Bellet D; Wands JR
Lab Invest; 1997 Jun; 76(6):859-71. PubMed ID: 9194861
[TBL] [Abstract][Full Text] [Related]
36. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160.
VanCott TC; Kaminski RW; Mascola JR; Kalyanaraman VS; Wassef NM; Alving CR; Ulrich JT; Lowell GH; Birx DL
J Immunol; 1998 Feb; 160(4):2000-12. PubMed ID: 9469464
[TBL] [Abstract][Full Text] [Related]
37. Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells.
Hinkula J; Walther-Jallow L; Laurén A; Mäkitalo B; Oberg M; Wahren B; Fenyö EM; Spetz AL
Vaccine; 2009 Oct; 27(46):6424-31. PubMed ID: 19549607
[TBL] [Abstract][Full Text] [Related]
38. Immune responses generated by Lactobacillus as a carrier in DNA immunization against foot-and-mouth disease virus.
Li YG; Tian FL; Gao FS; Tang XS; Xia C
Vaccine; 2007 Jan; 25(5):902-11. PubMed ID: 17028078
[TBL] [Abstract][Full Text] [Related]
39. Two mucosal-parenteral schedules to coadminister a multiantigenic formulation against HIV-1 in Balb/c mice.
Iglesias E; García D; Márquez G; Prieto YC; Sánchez J; Trimiño L; Soria Y; García D
Int Immunopharmacol; 2012 Mar; 12(3):487-93. PubMed ID: 22240123
[TBL] [Abstract][Full Text] [Related]
40. Recombinant virus-like particles of a norovirus (genogroup II strain) administered intranasally and orally with mucosal adjuvants LT and LT(R192G) in BALB/c mice induce specific humoral and cellular Th1/Th2-like immune responses.
Nicollier-Jamot B; Ogier A; Piroth L; Pothier P; Kohli E
Vaccine; 2004 Mar; 22(9-10):1079-86. PubMed ID: 15003634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
